Navigation Links
Molecular imaging detects recurrent prostate cancer

SALT LAKE CITYFindings of a clinical trial reported at SNM's 57th Annual Meeting indicate that a new molecular imaging agent could improve diagnosis of recurrent prostate cancer and determine the best possible course of treatment for patients.

"Despite definitive treatment, about 30 percent of prostate cancers recur," said David Schuster, M.D., director of the division of nuclear medicine and molecular imaging and assistant professor of radiology at Emory University School of Medicine, Atlanta, Ga. "This troubling statistic led our research team to diligently work on developing new techniques to more effectively detect and diagnose recurrent prostate tumors and associated cancers that have spread to nearby tissues and organs."

According to the authors, a radiotracer known as anti-18F-FACBC could be used to effectively and non-invasively detect and differentiate tumors recurring in the prostate and metastatic cancers that develop, most notably in the surrounding lymph nodes. "This may lead to custom-tailored treatments for prostate cancer patients that cater to their specific tumor type and progression of disease," added Schuster.

The new imaging agent, developed by Dr. Mark Goodman at Emory University, consists of a fluorine-based radioisotope paired with a synthetic amino-acid analog similar to the naturally-occurring amino acid L-leucine. Amino acids are essentially the building blocks of protein, and many cells have a system that controls the transport of amino acids into the cell in order to facilitate the production of new proteins. Upon injection, anti-18F-FACBC is absorbed by various cells by this transport system, but the "uptake," or admission of the agent, is much higher in aggressively multiplying cancer cells, which need more of these proteins in order to proliferate.

Researchers scanned 83 patients suspected of having recurrent prostate cancer using a hybrid positron emission tomography and computed tomography (PET/CT) system, a molecular imaging technique that displays both anatomical information and physiological processes in the body. Resulting scans were evaluated to determine the presence of recurrent prostate tumors and outlying tumors that had metastasized, or spread, to other tissues, including those of nearby bones and lymph nodes that tend be to a target for cancer metastases. The agent was able to positively identify recurrent carcinomas in the prostate region with 74-percent accuracy, and metastatic cancers with 96-percent accuracy, catching even small tumors within lymph nodes that other imaging agents could not detect. The ability to differentiate tumors recurring in the prostate from metastatic cancers with high accuracy is the most promising aspect of this PET radiotracer.


Contact: Amy Shaw
Society of Nuclear Medicine

Related medicine news :

1. Molecular Signatures in Post-Mortem Brain Tissue of Younger Individuals at High Risk for Alzheimer's Disease
2. Molecular imaging and CT colonography team up to bring comfort to patients
3. Acupunctures molecular effects pinned down
4. Salt Lake City proclaims Molecular Imaging Days during SNMs Annual Meeting in June
5. Scientists discover the molecular heart of collective behavior
6. News from Molecular Medicine
7. Molecular marker could help spot pancreatic cancer early
8. Molecular discovery points to new therapies for brain tumors
9. USC researchers discover new molecular subtype of brain cancer
10. The Association for Molecular Pathology celebrates ruling in DNA patent case
11. Scientists Discover Molecular Pathway for Organ Tissue Regeneration and Repair
Post Your Comments:
(Date:6/25/2016)... ... ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department of Health ... of their exemplary accomplishments in worksite health promotion. , The Wellness at Work Awards ... at the BWI Marriott in Linthicum Heights. iHire was one of 42 businesses to ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic events may ... to unhealthy avenues, such as drug or alcohol abuse, as a coping mechanism. To ... for healthy coping following a traumatic event. , Trauma sufferers tend to feel a ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... and Scientific Sessions in Dallas that it will receive two significant new grants ... grants came as PHA marked its 25th anniversary by recognizing patients, medical professionals ...
(Date:6/24/2016)... ... 2016 , ... Comfort Keepers® of San Diego, CA is excited to announce ... program to drive cancer patients to and from their cancer treatments. Comfort Keepers ... of life and ongoing independence. Getting to and from medical treatments is one ...
(Date:6/24/2016)... Georgia (PRWEB) , ... June 24, 2016 , ... ... awards today at the Clinical Decision Making in Emergency Medicine conference in Ponte ... have authored journal articles published in Emergency Medicine Practice and Pediatric ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... 2016 Capricor Therapeutics, Inc. ... biotechnology company focused on the discovery, development and ... enrollment in its ongoing randomized HOPE-Duchenne clinical trial ... of its 24-patient target. Capricor expects the trial ... of 2016, and to report top line data ...
(Date:6/23/2016)... PARK RIDGE, Ill. and INDIANAPOLIS ... caliber of students receiving a Lilly Diabetes Tomorrow,s Leaders ... hands. The 2016 scholarship winners, announced today online at ... refused to let type 1 diabetes stand in the ... Lilly Diabetes has supported the Foundation,s scholarship program since ...
(Date:6/23/2016)... June 23, 2016 The vast majority of ... dialysis facility.  Treatments are usually 3 times a week, ... visit, including travel time, equipment preparation and wait time. ... especially grueling for patients who are elderly and frail.  ... nursing and rehabilitation centers for some duration of time. ...
Breaking Medicine Technology: